The mechanism of aspirin-sensitive asthma remains unresolved, but it is known that the ability of drugs to cause symptoms in aspirinsensitive asthma is related to their potency as cyclooxygenase inhibitors.'0 It has been proposed that blockade of cyclooxygenase activity by these agents leads to diversion of arachidonic acid metabolism from the cyclooxygenase to the 5-lipoxygenase pathway with consequent increased leukotriene production." The evidence for the involvement of the cysteinyl leukotrienes in aspirin-sensitive asthma is compelling. Subjects with aspirin-sensitive asthma have six times higher basal levels of urinary LTE4 than aspirin-tolerant asthmatic and nonasthmatic subjects.'2 Furthermore, aspirin challenge of subjects with aspirin-sensitive asthma, which leads to bronchoconstriction, is accompanied by a mean fourfold increase in urinary LTE4 excretion.'2 No clinical symptoms or increase in urinary LTE4 levels are detected in non-aspirin-sensitive asthmatic individuals following aspirin ingestion. Additionally, there is increased target organ sensitivity to the bronchospastic effects of inhaled LTE4 in subjects with aspirin-sensitive asthma compared with aspirin-tolerant asthmatic subjects. '3 Previous studies have shown the efficacy of cysteinyl leukotriene receptor antagonists in the mechanisms of aspirin-sensitive asthma.'4'5 If leukotrienes are critical in the asthmatic response provoked by aspirin, one might expect an inhibitor of 5-lipoxygenase to block aspirin-sensitive asthma. We have tested this hypothesis with ZD2138, a novel non-redox lipoxygenase inhibitor'6 which is well tolerated and, at single oral doses of 350 mg or greater, inhibits ex vivo LTB4 synthesis in whole blood for 24 hours.'7 group.bmj.com on June 23, 2017 -Published by http://thorax.bmj.com/ Downloaded from
)% fall in FEVy following placebo compared with 4 9 (2-9)% following ZD2138. This was associated with 72% inhibition of ex vivo LTB4 generation in whole blood at 12 hours and a 74% inhibition of the rise in urinary LTE4 excretion at six hours after aspirin ingestion. Conclusions -In aspirin-sensitive asthma the 5-lipoxygenase inhibitor ZD2138 inhibits the fall in FEV, induced by aspirin and this is associated with substantial inhibition of 5-lipoxygenase. (Thorax 1994; 49:749-756) Asthmatic patients with aspirin-sensitive asthma' 2 are a readily identifiable group of subjects who develop bronchospasm on ingestion of aspirin or non-steroidal anti-inflammatory drugs. Other aspirin-induced symptoms in these subjects include rhinorrhoea, nasal The mechanism of aspirin-sensitive asthma remains unresolved, but it is known that the ability of drugs to cause symptoms in aspirinsensitive asthma is related to their potency as cyclooxygenase inhibitors.'0 It has been proposed that blockade of cyclooxygenase activity by these agents leads to diversion of arachidonic acid metabolism from the cyclooxygenase to the 5-lipoxygenase pathway with consequent increased leukotriene production." The evidence for the involvement of the cysteinyl leukotrienes in aspirin-sensitive asthma is compelling. Subjects with aspirin-sensitive asthma have six times higher basal levels of urinary LTE4 than aspirin-tolerant asthmatic and nonasthmatic subjects. ' (table 1) . Their resulting mean (SE) forced expiratory volume in one second (FEVy) was 2-57 (0-17)1 (mean predicted 86%; range 67-105%). All subjects also suffered with symptoms of rhinosinusitis comprising nasal congestion, rhinorrhoea, and varying degrees of dysosmia and loss of taste. The study was approved by the Guy's Hospital ethics committee and written informed consent was obtained from each subject.
STUDY PROTOCOL
Subjects were screened for aspirin sensitivity if they had a history of worsening asthma on aspirin ingestion. They were studied on three days, each separated by two weeks. On day 1 a medical history was taken and the subjects underwent general physical examination with an ECG. Blood was taken for a full blood count, clotting studies, estimation of electrolytes and urea, and liver function tests. Urine was examined by microscopy and tested for glucose, protein, and blood. Oral aspirin challenge was then performed with incremental doses of aspirin at two-hourly intervals, starting with 30 mg. The dose of aspirin resulting in a 20% or greater fall in FEV1 within two hours of ingestion was considered the threshold dose and used on days 2 and 3.
On days 2 and 3 350 mg ZD2138 (Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK) or matching placebo was given after an overnight fast in a randomised, double blind fashion. Four hours later aspirin challenge was performed with the threshold dose as determined on day 1. Continuous ambulatory ECG was monitored on days 2 and 3 for 24 hours. Urine was collected before drug or placebo administration and then immediately before and three, six, and nine hours after aspirin challenge. Blood for determination of ex vivo LTB4 generation was taken before and four (pre-aspirin), 12 was allowed to return to within 10% of baseline before the next dose was administered. The dose that elicited a fall in FEVI of 20% or more was considered the threshold dose. On study days 2 and 3 the threshold dose of aspirin was administered four hours after dosing with placebo or ZD 2138 and FEVI was measured at 15 minute intervals for two hours and then hourly until six hours after aspirin administration. All subjects were asked to report any new symptoms or change in symptoms after aspirin ingestion from the baseline period and these were recorded. Antihistamines were discontinued for 48 hours, inhaled and nasal corticosteroids for 24 hours, and salbutamol for at least eight hours before each study day until 24 hours after aspirin challenge.
MEASUREMENT OF URINARY LTE4
The free radical scavenger 4-hydroxy-2,2,6,6-tetramethylpiperidinooxy free radical (4-hydroxy-TEMPO; Sigma Chemical Company, Poole, Dorset, UK) was added to each urine sample immediately after collection to a final concentration of 1 mmol/l, the samples were adjusted to pH 9 with NaOH to stabilise endogenous leukotriene metabolites and stored at -70°C until analysed. Urinary LTE4 levels were measured as described previously. ' 10 mmol/l Tris HCl buffer (pH 7 4). The concentration of immunoreactive LTE4 was assessed by radioimmunoassay as described previously.'9 Urinary creatinine concentrations were measured (Mira Analyser, Hoffman Roche, Welwyn) by the kinetic picrate method, without deproteinisation.20 LTE4 concentrations were expressed as pg/mg creatinine and were calculated from measured immunoreactivity minus background, corrected for recovery and dilution.
MEASUREMENT OF EX VIVO LTB4
The ability of ZD2138 to inhibit 5-lipoxygenase was also assessed by measurement of calcium ionophore-stimulated ex vivo LTB4 production in whole blood. Blood was collected into heparinised tubes and calcium ionophore (A23187) added to 500 g1 whole blood in triplicate to a final concentration of 2 5 pmol/l. The blood was incubated for 20 minutes at 37°C, centrifuged at 3600 rpm for one minute, and the supernatant stored at -20°C. LTB4 was assayed subsequently by radioimmunoassay, as previously described.2'
DATA ANALYSIS
The area under the FEV,-time curve following administration of placebo or ZD2138 was calculated for the four hours before aspirin challenge to assess bronchodilatation and for the six hours after aspirin challenge and analysed nonparametrically by the Wilcoxon signed rank test. Using linear regression analysis, the percentage inhibition of urinary LTE4 was correlated with the degree of protection by ZD2138 against a fall in FEV, for each of the periods 4-0, 0-2, and 2-6 hours after aspirin ingestion. Baseline FEVI and urinary LTE4 values were also correlated with the degree of bronchodilatation in each individual using linear regression analysis. The urinary LTE4 values were expressed as pg/mg creatinine and the area under the urinary LTE4-time curve for the drug and placebo days were also compared using the Wilcoxon signed rank test. Data for LTB4 values were only available for five of the seven subjects because of technical difficulties with the other samples. All data points are expressed as mean (SE). 
SUBJECTS
On the screening day all subjects experienced symptoms of wheeze following aspirin ingestion and, in addition, subjects 1, 2, 3,6, and 7 experienced rhinorrhoea and nasal congestion. Table  2 describes the symptoms experienced by the subjects on the study days. In all subjects ZD2138 premedication reduced aspirininduced symptoms.
AIRWAY RESPONSES
The resting FEVI before drug administration was significantly lower on the ZD2138 day (2 361) than on the placebo day (2 71; p < 005). Figure 1 shows the mean change in FEVy for four hours after administration of placebo or ZD2138. FEV1 rose by 7 (2 3)% at three hours after administration of ZD2138 compared with a fall of 4 ( 3 9 Time after ZD2138 or placebo administration (hours) Figure 1 Percentage change in FEV, for the four hours after administration of ZD2138 ( 0 ) or placebo ( 0 ), and before aspirin challenge. Time after aspirin challenge (hours) Figure 2 Mean (SE) percentage change in FEV, for six hours after aspirin challenge. ZD2138 ( 0 ) or placebo (0) was administered four hours before aspirin challenge. Based on the fall in FEV, and the difference between drug (D) and placebo (P) days, each subject has been categorised as a responder (R), partial responder (PR), or non-responder (NR) to ZD2138. NE = non-evaluable.
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there was a mean maximal fall in FEVI of 20 3 (4 9)% six hours after administration of aspirin compared with 4 9 (2 9)% on the ZD2138 day. Individual data are shown in fig 3. Ir. subjects 3 and 5 there was complete inhibition and in subjects 1,2, and 7 there was partial protection of the aspirin-induced asthmatic reaction. In subject 4 there was no inhibitory effect of the 5-lipoxygenase inhibitor on aspirin-provoked bronchoconstriction.
The effects of ZD2138 on aspirin-induced responses are similarly apparent if the maximal falls in FEV, in the first two hours and for the 2-6 hour period are analysed. In the first two hours five of the seven individuals clearly showed attenuation of the aspirin-induced response by active drug. Subject 4 could not be evaluated during the first two hours because she did not have a significant fall in FEVP. Simi- larly, for the 2-6 hour period five of the seven individuals showed a response (table 3) .
There was no significant correlation between inhibition of urinary LTE4 levels and protection by ZD2138 against a fall in FEVI induced by aspirin for the periods -4-0 hours (r = 0 37; p < 0 5), 0-2 hours (r = 0 43; p < 0 5), and 2-6 hours (r = 0 3; p = 0 5) after aspirin ingestion. Figure 4 shows the mean ionophore-induced generation of LTB4 from whole blood after administration of placebo and ZD2138. The baseline LTB4 levels were 102 4 (30) ztg/ml and 97 1 (26) ptg/ml on the ZD2138 and placebo days, respectively. There was substantial inhibition of ex vivo generation of whole blood LTB,; compared with placebo there was an average 57% inhibition at four hours, 72% inhibition at 12 hours, and 76% at 24 hours after dosing with ZD2138.
INHIBITION OF EX VIVO GENERATION OF LTB4

URINARY LTE4
There was no significant difference between baseline urinary LTE4 levels on the two days ( fig 5) . On the placebo day urinary LTE4 levels did not change significantly from the baseline value of 391 (72) 10 hours, and 59% at 13 hours after dosing with ZD2138. Significantly less urinary LTE4 excretion was seen after ZD2138 than after administration of placebo (p < 0 05).
ZD2138 was well tolerated and no adverse events attributed to the drug occurred in the study. All seven subjects completed the study.
Discussion
The ability of ZD2138 to modulate aspirininduced asthma has been investigated in seven asthmatic subjects with aspirin sensitivity. ZD2138 is a novel non-redox 5-lipoxygenase inhibitor which is derived from a unique enantioselective series. It is well tolerated and at single oral doses of 350 mg or more inhibits leukotriene synthesis for 24 hours.'7 The drug was given to fasted subjects to standardise bioavailability. The study was designed so that aspirin provocation was undertaken four hours after drug administration when the plasma level of the drug is anticipated to be maximal. Changes in pulmonary function were measured using FEV,, and the effectiveness of 5-lipoxygenase inhibition was assessed by measuring LTB4 generation of calcium ionophore-activated whole blood leucocytes and excretion of immunoreactive LTE4 into the urine.
We have shown that 5-lipoxygenase inhibition by ZD2138 leads to significant bronchodilatation and protection against the fall in FEVI induced by oral aspirin challenge in individuals with aspirin-sensitive asthma. In addition, each patient experienced significantly fewer naso-ocular and/or systemic symptoms in response to aspirin after dosing with ZD2138 compared with placebo. The reduction in systemic symptoms was observed even in the individual who showed no amelioration of the decrement in FEV, following aspirin ingestion after premedication with the active drug (subject 4).
The heterogeneity of FEV, responses to the inhibitory effects of antileukotriene drugs has been reported previously. '4 This may reflect heterogeneity of mechanisms for aspirin-sensitive asthma, inadequate 5-lipoxygenase inhibition in some individuals, or involvement of other mediators in the bronchoconstriction produced by aspirin-sensitive asthma. In this regard, naso-ocular symptoms induced by either oral aspirin or inhaled lysine-aspirin are associated with histamine release into nasal lavage fluid.2223 Bosso et Time relative to aspirin challenge (h) Figure 3 Individual graphs for all seven subjects demonstrating the percentage change in FEV, for six hours following aspirin challenge. ZD2138 ( * ) or placebo ( 0 ) was administered four hours before aspirin challenge. In contrast to the present study ZD2138 did not protect against allergen-induced asthma. 28 The designs of the allergen and aspirin challenge studies were identical and the dose of ZD2138 used in both studies was the same. This suggests that the mechanisms for allergenand aspirin-induced bronchoconstrictions are different. Aspirin-induced asthma appears to be more dependent on 5-lipoxygenase pathway metabolites. This is supported by our previous finding that asthmatic patients with aspirin sensitivity have higher basal levels of LTE4 excretion in the urine than asthmatic patients without aspirin sensitivity,'2 18 and the observation that subjects with aspirin-sensitive asthma are considerably more sensitive to the bronchoconstrictor effects of inhaled LTE4 than aspirin-tolerant asthmatic subjects. ' 5- lipoxygenase by ZD2138 led to a substantial attenuation of the pulmonary response to aspirin in these patients.
